 -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 GLOBE NEWSWIRE -- Pacira BioSciences, Inc. Nasdaq: PCRX, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a 3 million investment in Spine BioPharma in the form of a convertible note. The investment will support the advancement of Spine BioPharmas lead candidate, RemediscTM, a first-in-class therapeutic for the treatment of degenerative disc disease. Pacira will make an additional 7 million investment predicated upon Spine BioPharma achieving certain prespecified milestones. 